Cardima Revelation Tx Trial Results Show 45% Cure Rate For AF Episodes
This article was originally published in The Gray Sheet
Executive Summary
Cardima is hoping that clinical data showing 85% of patients had a reduction in their AF episodes of greater than or equal to 50% after being treated with its Revelation Tx system will prompt FDA's Circulatory System Devices Panel to recommend approval
You may also be interested in...
Cardima’s Revelation: AF Self-Monitoring, Hazy Endpoints Hamper Review
The ability of self-reporting to accurately track reduction in atrial fibrillation burden is cast into doubt by FDA panel experience with Cardima's Revelation ablation system data submission
Cardima’s Revelation: AF Self-Monitoring, Hazy Endpoints Hamper Review
The ability of self-reporting to accurately track reduction in atrial fibrillation burden is cast into doubt by FDA panel experience with Cardima's Revelation ablation system data submission
CardioFocus Illuminates Underserved “AF-Alone” Market With Light Ring
CardioFocus expects its Light Ring catheter to be among the first devices to cure drug-resistant paroxysmal atrial fibrillation (AF) in patients not indicated for surgery